Back to News

Kevin Raidy

Kevin Raidy is a Managing Director at Blue Owl and the Head of Healthcare Opportunities. In this role, he oversees all private and public investment activity related to Healthcare Opportunities and sits on the Fund’s Investment Committee. 

Previously, Kevin was a founder and Managing Partner of Cowen Healthcare Investments, the predecessor to Blue Owl Healthcare Opportunities. Prior to his role at Cowen Healthcare Investments, Kevin was Cowen’s Head of Investment Banking and prior to that he was Co-Head of Cowen’s Equity Capital Markets Group. Before that Kevin was a Managing Director at Ramius LLC where he was responsible for direct investments and convertible bonds. Kevin’s sell side experience includes ten years at Shipley Raidy Capital Partners, a boutique investment banking firm which he co-founded. Prior to founding Shipley Raidy, Kevin was an associate at Philadelphia First Group. He started his career at Cantor Fitzgerald before moving to Merrill Lynch as an analyst in the municipal finance group. 

He is currently a member of the Board of Directors of NodThera Ltd, Escient Pharmaceuticals, Neuron23, and Aro Biopharmaceuticals, while also a Board Observer at Delfi Diagnostics, Aktis Oncology and Evox Therapeutics. 

Kevin received a BS in Economics with a concentration in Finance from the Wharton School of the University of Pennsylvania.